Successful use of mycophenolate mofetil and prednisone in a 14-year-old girl with acquired hemophilia A

Eisert, S; Mosler, Katharina; Hj, Laws; Göbel, U.

doi:10.1055/s-0037-1616782

Cited by 11 publications

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Acquired hemophilia in pediatrics: A systematic review

Franchini

Zaffanello

Lippi

2010

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Acquired hemophilia A is a rare but potentially life-threatening hemorrhagic disorder caused by the development of autoantibodies directed mostly against coagulation factor VIII. Acquired hemophilia is frequently associated with several underlying conditions such as malignancy, autoimmune disorders, drug reactions, and pregnancy, although the pathogenesis remains undetermined (idiopathic) in up to 50% of reported cases. The disorder occurs most commonly in the elderly and only rarely affects pediatric patients, who might however experience severe, and sometimes life-threatening, hemorrhage. The maternal transplacental transfer of the autoantibody to the neonate occurs very rarely and also in this circumstance it may be associated with clinically significant bleeding. The management of acute bleeding and the inhibitor eradication are the mainstay of the treatment. The outcome in pediatric patients seems more favorable than in adults because the inhibitors usually resolve more quickly and in a higher rate of patients. The epidemiology, diagnosis, clinical course, and management of this hemorrhagic disorder in children will be addressed in this systematic review.

show abstract

Acquired hemophilia in pediatrics: A systematic review

Franchini

Zaffanello

Lippi

2010

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

Bleeding Associated with Coagulation Factor Inhibitors

Eby

2021

Management of Bleeding Patients

View full text Add to dashboard Cite

Diagnosis, laboratory aspects and management of acquired hemophilia A

Toschi

Baudo

2010

Intern Emerg Med

View full text Add to dashboard Cite

Acquired hemophilia A (AHA) is a rare autoimmune disease, characterized by severe, often life-threatening hemorrhages in patients without a prior history of bleeding disorder. It most frequently occurs in the elderly, and may be associated with other clinical conditions, such as cancer, autoimmune diseases, pregnancy or without a relevant cause. Diagnosis and correct therapy are crucial for the patient's outcome. Management of the disease consists of gaining immediate control of acute bleeding and the starting of an immunosuppressive therapy in order to eradicate the anti-factor VIII autoantibody. Factor VIII bypassing agents, such as prothrombin complex concentrates or recombinant activated factor VII, have proven effective in bleeding control, whereas the combined therapy of cyclophosphamide and corticosteroids seems to be, at present, the best immunosuppressive option. Other treatments including Rituximab, immunoadsorption or induction of immune tolerance are still experimental, and need to be validated through controlled clinical trials.

show abstract

Successful use of mycophenolate mofetil and prednisone in a 14-year-old girl with acquired hemophilia A

Cited by 11 publications

References 6 publications

Acquired hemophilia in pediatrics: A systematic review

Acquired hemophilia in pediatrics: A systematic review

Bleeding Associated with Coagulation Factor Inhibitors

Diagnosis, laboratory aspects and management of acquired hemophilia A

Contact Info

Product

Resources

About